tetano
Editor, Senior Moderator
Viruses
. 2023 Nov 16;15(11):2264.
doi: 10.3390/v15112264. Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
Keita Fukao[SUP] 1 [/SUP], Takeshi Noshi[SUP] 1 [/SUP], Shinya Shano[SUP] 2 [/SUP], Kaoru Baba[SUP] 2 [/SUP], Kenji Sato[SUP] 1 [/SUP], Masashi Sakuramoto[SUP] 1 [/SUP], Naohisa Kitade[SUP] 1 [/SUP], Hideki Tanioka[SUP] 1 [/SUP], Shinji Kusakabe[SUP] 1 [/SUP], Takao Shishido[SUP] 1 [/SUP]
Affiliations
Influenza remains a worldwide health concern. Antiviral drugs are considered as one of the useful options for its prevention as a complementary measure to vaccination. Baloxavir acid selectively inhibits the cap-dependent endonuclease of influenza viruses and exhibits marked viral titre reduction in patients. Here, we describe the prophylactic potency of baloxavir acid against lethal infection with influenza A and B viruses in mice. BALB/c mice were subcutaneously administered once with baloxavir acid suspension, or orally administered once daily for 10 days with oseltamivir phosphate solution at human relevant doses. Next, the mice were intranasally inoculated with A/PR/8/34 (H1N1) or B/Hong Kong/5/72 strain at 24 to 96 h after the initial dosing. Prophylactic treatment with the antiviral drugs significantly reduced the lung viral titres and prolonged survival time. In particular, baloxavir acid showed a greater suppressive effect on lung viral titres compared to oseltamivir phosphate. In this model, baloxavir acid maintained significant prophylactic effects against influenza A and B virus infections when the plasma concentration at the time of infection was at least 0.88 and 3.58 ng/mL, respectively. The significant prophylactic efficacy observed in our mouse model suggests the potential utility of baloxavir marboxil for prophylaxis against influenza in humans.
Keywords: baloxavir acid; baloxavir marboxil; cap-dependent endonuclease inhibitor; influenza virus; oseltamivir phosphate; prophylaxis.
. 2023 Nov 16;15(11):2264.
doi: 10.3390/v15112264. Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
Keita Fukao[SUP] 1 [/SUP], Takeshi Noshi[SUP] 1 [/SUP], Shinya Shano[SUP] 2 [/SUP], Kaoru Baba[SUP] 2 [/SUP], Kenji Sato[SUP] 1 [/SUP], Masashi Sakuramoto[SUP] 1 [/SUP], Naohisa Kitade[SUP] 1 [/SUP], Hideki Tanioka[SUP] 1 [/SUP], Shinji Kusakabe[SUP] 1 [/SUP], Takao Shishido[SUP] 1 [/SUP]
Affiliations
- PMID: 38005940
- PMCID: PMC10675732
- DOI: 10.3390/v15112264
Influenza remains a worldwide health concern. Antiviral drugs are considered as one of the useful options for its prevention as a complementary measure to vaccination. Baloxavir acid selectively inhibits the cap-dependent endonuclease of influenza viruses and exhibits marked viral titre reduction in patients. Here, we describe the prophylactic potency of baloxavir acid against lethal infection with influenza A and B viruses in mice. BALB/c mice were subcutaneously administered once with baloxavir acid suspension, or orally administered once daily for 10 days with oseltamivir phosphate solution at human relevant doses. Next, the mice were intranasally inoculated with A/PR/8/34 (H1N1) or B/Hong Kong/5/72 strain at 24 to 96 h after the initial dosing. Prophylactic treatment with the antiviral drugs significantly reduced the lung viral titres and prolonged survival time. In particular, baloxavir acid showed a greater suppressive effect on lung viral titres compared to oseltamivir phosphate. In this model, baloxavir acid maintained significant prophylactic effects against influenza A and B virus infections when the plasma concentration at the time of infection was at least 0.88 and 3.58 ng/mL, respectively. The significant prophylactic efficacy observed in our mouse model suggests the potential utility of baloxavir marboxil for prophylaxis against influenza in humans.
Keywords: baloxavir acid; baloxavir marboxil; cap-dependent endonuclease inhibitor; influenza virus; oseltamivir phosphate; prophylaxis.